Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

Resource Type

CF Research News

Authors

Ido Sadras, Eitan Kerem, Galit Livnat, Ifat Sarouk, Oded Breuer, Joel Reiter, Alex Gileles-Hillel, Ori Inbar, Michael Cohen, Ayelet Gamliel, Noemie Stanleigh, Tarini Gunawardena, Claire Bartlett, Tanja Gonska, Theo Moraes, Paul D W Eckford,
Christine E Bear, Felix Ratjen, Batsheva Kerem, Michael Wilschanski, Michal Shteinberg, Malena Cohen-Cymberknoh

References

J Cyst Fibros. 2023 Jun 16;S1569-1993(23)00178-9. doi: 10.1016/j.jcf.2023.06.001.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Theme

Pulmonology [3]

Date

Friday, June 16, 2023

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [4]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/elexacaftortezacaftorivacaftor-improves-cftr-activity-and-0

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-22-00467R1_FINAL_Sadras_230723.pdf [2] https://pubmed.ncbi.nlm.nih.gov/37331863/ [3] https://www.ecfs.eu/research-article-themes/pulmonology [4] https://www.ecfs.eu/resource-guideline-type/other-guidelines